Telix gives dose to first patient in prostate cancer trial

By staff writers

August 14, 2023 -- Telix Pharmaceuticals has announced that the first patient has been dosed in a trial in China to test its PET radiotracer injection kit Illuccix for prostate cancer imaging.

Illuccix is a kit for preparing gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 PET radiotracer injections in patients with advanced prostate cancer. The study is required to establish that the diagnostic utility of Illuccix is equivalent in Chinese and Western populations. Illuccix was cleared by the U.S. Food and Drug Administration in March.

The study will enroll up to 110 patients with relapsed prostate cancer, with data to support a future marketing authorization application for the kit in China, Telix added.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking